Chromatin Remodulator CHD4: A Potential Target for Cancer Interception
Genes · 2025
DOI: 10.3390/genes16020225 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Krishnendu Goswami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma HSC, Okl…. Hauptthemen laut MEDLINE: Neoplasms, Mi-2 Nucleosome Remodeling and Deacetylase Complex, Chromatin Assembly and Disassembly, DNA Helicases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCI NIH HHS, NCI.
Abstract (Originalsprache)
Cancer initiation and progression are associated with numerous somatic mutations, genomic rearrangements, and structure variants. The transformation of a normal cell into a cancer cell involves spatio-temporal changes in the regulation of different gene networks. The accessibility of these genes within the cell nucleus is manipulated via nucleosome remodeling ATPases, comprising one of the important mechanisms. Here, we reviewed studies of an ATP-dependent chromatin remodulator, chromodomain helicase DNA-binding 4 (CHD4), in cancer. Multiple domains of CHD4 are known to take part in nucleosome mobilization and histone binding. By binding with other proteins, CHD4 plays a vital role in transcriptional reprogramming and functions as a key component of Nucleosome Remodeling and Deacetylase, or NuRD, complexes. Here, we revisit data that demonstrate the role of CHD4 in cancer progression, tumor cell proliferation, DNA damage responses, and immune modulation. Conclusively, CHD4-mediated chromatin accessibility is essential for transcriptional reprogramming, which in turn is associated with tumor cell proliferation and cancer development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma HSC, Oklahoma City, OK 73104, USA.
- VA Medical Center, Oklahoma City, OK 73104, USA.
ORCID-Profile: Karthikkumar Venkatachalam, Surya P Singh, Chinthalapally V Rao, Venkateshwar Madka
Förderung
- BLRD VA
- NCI NIH HHS
- NCI
- American Cancer Society
- Kerley-Cade Endowed Chair
Zitieren
APA
Goswami, K., Venkatachalam, K., Singh, S. P., Rao, C. V., & Madka, V. (2025). Chromatin Remodulator CHD4: A Potential Target for Cancer Interception. Genes. https://doi.org/10.3390/genes16020225
Vancouver
Goswami K, Venkatachalam K, Singh SP, Rao CV, Madka V. Chromatin Remodulator CHD4: A Potential Target for Cancer Interception. Genes. 2025. doi:10.3390/genes16020225
BibTeX
@article{Goswami2025,
author = {Goswami, Krishnendu and Venkatachalam, Karthikkumar and Singh, Surya P and Rao, Chinthalapally V and Madka, Venkateshwar},
title = {Chromatin Remodulator CHD4: A Potential Target for Cancer Interception},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16020225}
}
EUVIMED